PMID- 21352258
OWN - NLM
STAT- MEDLINE
DCOM- 20110921
LR  - 20181201
IS  - 1600-0560 (Electronic)
IS  - 0303-6987 (Linking)
VI  - 38
IP  - 6
DP  - 2011 Jun
TI  - EGFR in melanoma: clinical significance and potential therapeutic target.
PG  - 492-502
LID - 10.1111/j.1600-0560.2011.01673.x [doi]
AB  - BACKGROUND: The role of epidermal growth factor receptor (EGFR) has been 
      established in a range of neoplasms. In melanoma, data on EGFR protein expression 
      are conflicting. Fluorescence in situ hybridization (FISH) analysis for EGFR gene 
      expression in melanoma showed EGFR gene amplification to be linked with worse 
      prognosis. Cetuximab has been shown to suppress the formation of metastasis in 
      mice. METHODS: EGFR protein expression and gene copy number status were evaluated 
      by means of immunohistochemistry and FISH in melanoma samples of patients with 
      known clinicopathological data. Associations between EGFR expression and 
      prognostic parameters were investigated. The effect of different cetuximab 
      concentrations on the BLM melanoma cell line was evaluated by means of methyl 
      tetrazolium (MTT), sulforhodamine B (SRB) and Matrigel invasion assays. RESULTS: 
      EGFR protein expression was more frequently observed in patients with a positive 
      sentinel lymph node. However, EGFR immunostaining has no predictive value. The 
      presence of EGFR polysomy was associated with thicker tumors. Treatment of the 
      BLM melanoma cell line with different concentrations of cetuximab reduced the 
      invasive capacity of the cells, but did not alter cell viability or growth. 
      CONCLUSION: EGFR appears to be involved in progression and metastasis of a subset 
      of melanomas. Targeting EGFR could therefore represent a therapeutic option for 
      these melanomas.
CI  - Copyright (c) 2011 John Wiley & Sons A/S.
FAU - Boone, Barbara
AU  - Boone B
AD  - Department of Dermatology, University Hospital Ghent, Ghent, Belgium. 
      barbara.boone@ugent.be
FAU - Jacobs, Koen
AU  - Jacobs K
FAU - Ferdinande, Liesbeth
AU  - Ferdinande L
FAU - Taildeman, Jasmien
AU  - Taildeman J
FAU - Lambert, Jo
AU  - Lambert J
FAU - Peeters, Marc
AU  - Peeters M
FAU - Bracke, Marc
AU  - Bracke M
FAU - Pauwels, Patrick
AU  - Pauwels P
FAU - Brochez, Lieve
AU  - Brochez L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110224
PL  - United States
TA  - J Cutan Pathol
JT  - Journal of cutaneous pathology
JID - 0425124
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Blotting, Western
MH  - ErbB Receptors/biosynthesis/*genetics
MH  - Female
MH  - Gene Dosage
MH  - Gene Expression
MH  - *Gene Expression Profiling
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Melanoma/*genetics/pathology
MH  - Middle Aged
MH  - Prognosis
MH  - Skin Neoplasms/*genetics/pathology
EDAT- 2011/03/01 06:00
MHDA- 2011/09/22 06:00
CRDT- 2011/03/01 06:00
PHST- 2011/03/01 06:00 [entrez]
PHST- 2011/03/01 06:00 [pubmed]
PHST- 2011/09/22 06:00 [medline]
AID - 10.1111/j.1600-0560.2011.01673.x [doi]
PST - ppublish
SO  - J Cutan Pathol. 2011 Jun;38(6):492-502. doi: 10.1111/j.1600-0560.2011.01673.x. 
      Epub 2011 Feb 24.